Saptalis Pharmaceuticals LLC announced in a press release the commercial launch of cyclosporine ophthalmic emulsion 0.05%, the generic equivalent of Restasis (AbbVie) for the treatment of dry eye disease. Available in 30- and 60-count single-use vials, cyclosporine ophthalmic emulsion 0.05% is a preservative-free, single-use formulation indicated to increase tear production and manage inflammation-associated tear deficiency.

Alongside the ophthalmic product offering, the company also announced the approval and launch of several other products across dermatology, psychiatry, and allergy-related therapeutic areas. OM